These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Hyperleukocytosis from arsenic trioxide. Levy M; Wofford MM; Powell BL; McLean TW Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308 [TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide in the management of acute promyelocytic leukaemia. Mathews V; Chandy M; Srivastava A Natl Med J India; 2001; 14(4):215-22. PubMed ID: 11547528 [TBL] [Abstract][Full Text] [Related]
9. Clinical usefulness of arsenic trioxide in the treatment of acute promyelocytic leukemia. Lo Coco F Haematologica; 2002 May; 87(5):452-3. PubMed ID: 12010655 [No Abstract] [Full Text] [Related]
11. Advances in management of acute promyelocytic leukemia with arsenic trioxide. Ma J Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904 [No Abstract] [Full Text] [Related]
12. Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia. Ianotto JC; Tempescul A; Eveillard JR; Charles F; Berthou C Acta Haematol; 2010; 123(3):146-7. PubMed ID: 20134156 [No Abstract] [Full Text] [Related]
13. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia. Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432 [No Abstract] [Full Text] [Related]
14. Clinical efficacy of arsenic trioxide in a patient with acute promyelocytic leukemia with recurrent central nervous system involvement. Zappasodi P; Rossi M; Ambaglio I; Bernasconi P; Corso A; Lazzarino M; Castagnola C Ann Hematol; 2011 May; 90(5):595-7. PubMed ID: 20721555 [No Abstract] [Full Text] [Related]
15. Comparing two arsenic trioxide administration methods in APL therapy. Zhou J; Meng R; Yang BF Chin Med J (Engl); 2004 Sep; 117(9):1411-3. PubMed ID: 15377438 [No Abstract] [Full Text] [Related]
16. Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies. Tallman MS Blood Rev; 2001 Sep; 15(3):133-42. PubMed ID: 11735161 [No Abstract] [Full Text] [Related]
18. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309 [TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide for the treatment of a relapsed acute promyelocytic leukemia with acute renal failure. Yoon HS; Park TS; Jeong KH Pediatr Blood Cancer; 2011 Dec; 57(6):1085. PubMed ID: 21656902 [No Abstract] [Full Text] [Related]
20. Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid. Breccia M; Molica M; Efficace F; Minotti C; Latagliata R; Foà R; Lo Coco F Br J Haematol; 2014 Nov; 167(3):428-30. PubMed ID: 24957334 [No Abstract] [Full Text] [Related] [Next] [New Search]